Nationwide Fund Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Nationwide Fund Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-19,391	Closed	-$481K	–	2642
2017 Q3	$481K	Sell	19,391 -506	-3%	-$10.9K	﹤0.01%	2208
2017 Q2	$409K	Sell	19,897 -198	-1%	-$3.78K	﹤0.01%	2282
2017 Q1	$437K	Buy	20,095 +3,851	+24%	+$79K	﹤0.01%	2227
2016 Q4	$332K	Sell	16,244 -685	-4%	-$14K	﹤0.01%	2386
2016 Q3	$254K	Hold	16,929	–	–	﹤0.01%	2520
2016 Q2	$183K	Buy	16,929 +9,495	+128%	+$129K	﹤0.01%	2656
2016 Q1	$101K	Hold	7,434	–	–	﹤0.01%	2818
2015 Q4	$137K	Buy	7,434 +4,704	+172%	+$87K	﹤0.01%	2726
2015 Q3	$69K	Buy	+2,730	New	+$63.8K	﹤0.01%	2980

Other funds holding AIMT

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Nationwide Fund Advisors's AIMT Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2017, closing a stake of 19,391 shares — an estimated $481K sold.

Nationwide Fund Advisors first reported a position in AIMT in Q3 2015 and held it in 9 quarters. The position peaked at $481K in Q3 2017. 129 funds tracked by Wall St. Rank hold AIMT as of Q4 2017.

Nationwide Fund Advisors reported no remaining Aimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 19,391 Aimmune Therapeutics shares in Q4 2017, an estimated $481K.
Nationwide Fund Advisors first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 9 quarters.
Nationwide Fund Advisors's Aimmune Therapeutics position peaked at $481K in Q3 2017.
129 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.